Deadline for manuscript submissions: 30 November 2021Print Special Issue Flyer (0)
MD, PhD, San Filippo Neri Hospital, Department of Urology, Rome, Italy
Interests: Surgical Oncology, Prostate Cancer, Urologic Oncology, Kidney, Endourology, Urinary Incontinence, Prostate, Urolithiasis, Bladder Cancer, Surgical Techniques
Lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) are widespread in the elderly population and are one of the main causes for resorting to a urological examination.
The treatment of LUTS/BPE is certainly a successful story in the field of urology. Historically, open surgery was the only viable option for the BPE treatment, mainly reserved for the treatment of its complications. Ameliorations in surgical equipment and the advent of novel technologies increased progressively the use of (very) minimally invasive for the treatment of LUTS secondary to BPE. Moreover in recent years, the introduction of several different pharmacological treatments for LUTS/BPE has changed drastically our clinical practice. Six classes of drugs [alpha blockers (ABs), 5-alpha reductase inhibitors (5ARIs), phytotherapeutics, anti-muscarinics (AMs), beta-3 agonists and phosphodiesterase type 5 inhibitors (PDE5I)] are currently on the market alone or in combination for the treatment of LUTS/BPE patients, significantly modifying their management.
Therefore, this wealth of therapeutic options allows the urologist to tailor the most suitable treatment to each patient, such as a bespoke suit for each prostate. The downside is that all these alternatives can create uncertainty in the clinician on the choice of treatment and false expectations in the patient, often attracted by the latest news on the market rather than by the one most suitable for its characteristics.
The purpose of this special issue of the journal is to help our readers to better navigate this maze, in order to better define the position of each treatment in the armamentarium of therapies for LUTS/BPE and to better define the subgroups of patients who will benefit most from them.
Dr. Fabrizio Presicce
Treatment, LUTS, BPE
Submissions will be accepted on a rolling basis and reviewed by experts in the field. Rapid peer review and prompt editorial decisions will ensure that quality manuscripts are published on time. The manuscript has not already been published or submitted elsewhere (except conference proceedings papers). If similar work has been published or submitted elsewhere, you must provide a copy of the submitted manuscript. You may not submit your manuscript elsewhere while it is under consideration at the Journal of Men's Health. All manuscripts undergo thorough double-blind peer-review. To check the suitability of the special issue for publishing your manuscript, please read the journal's aims and scope and read or download the guide for authors. You may also send a brief abstract of your work (about 100 words) to the Editorial Office at firstname.lastname@example.org. A guide for authors and other relevant information for manuscript submission is available on the Instructions for Authors page.
Academic Writing and English Language Editing Services
Authors who feel that their manuscript may benefit from additional academic writing or language editing support before submission are strongly encouraged to use academic editing services.
Article Processing Charges (APC)
All manuscripts submitted to the Journal of Men's Health are assessed according to the journal standard editorial criteria. If accepted for publication, an Article Processing Charge of 900 USD applies.
The journal typically offers a 30% discount to submissions with good quality invited by the Editor-in-Chief, Guest Editor (GE), Editorial Board Member and Reviewer Board Member.
Type of Articles: Original Research, Review, Mini-Review, Systematic Review, Short Communication, Case Report, Letter to the Editor, Commentary, Rapid Report, Meeting Report, News and Views
Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.
Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.
CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.
Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.